Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors :: Cannon, Christopher P.
Blazing, Michael A.
Giugliano, Robert P.
McCagg, Amy
White, Jennifer A.
Theroux, Pierre
Darius, Harald
Lewis, Basil S.
Ophuis, Ton Oude
Jukema, J. Wouter
De Ferrari, Gaetano M.
Ruzyllo, Witold
De Lucca, Paul
KyungAh Im
Bohula, Erin A.
Reist, Craig
Wiviott, Stephen D.
Tershakovec, Andrew M.
Musliner, Thomas A.
Braunwald, Eugene
Source :: New England Journal of Medicine. 6/18/2015, Vol. 372 Issue 25, p2387-2397. 11p.
Publication Year :: 2015
Abstract: The article discusses a study that added nonstatin drug ezetimibe to determine its ability of reducing absorption of intestinal cholesterol for reducing cardiovascular events. Topics covered include randomized trial on 18,144 patients with acute coronary syndrome and 50-100 milligrams per deciliter (mg/deciliter) low-density lipoprotein (LDL) levels. Results showed lower Kaplan-Meier events in the simvastatin-ezetimibe patients group than those in the simvastatin-monotherapy group.